Efficacy of ketamine in relieving neuropathic pain: a systematic review and meta-analysis of animal studies

Monique van Velzen, Jack D C Dahan, Eveline L A van Dorp, Jeffrey S Mogil, Carlijn R Hooijmans, Albert Dahan, Monique van Velzen, Jack D C Dahan, Eveline L A van Dorp, Jeffrey S Mogil, Carlijn R Hooijmans, Albert Dahan

Abstract

In humans, proof of long-term efficacy of ketamine treatment in neuropathic pain is lacking. To improve our understanding of ketamine behavior under various administration conditions, we performed a systematic review and meta-analyses of controlled studies on the efficacy of ketamine in mice and rats with a disease model of nerve injury on relief of allodynia. Searches in PubMed and EMBASE identified 31 unique studies. Four meta-analyses were conducted. The first analysis included 19 comparisons on a single ketamine dose and measurement of effect within 3 hours of dosing and showed an appreciable effect (standardized mean difference 1.6, 95% confidence interval 1.1-2.1). Subgroup analyses showed no effect of species, administration route, or dose. A single administration was insufficient to sustain relief of allodynia at 24 or 72 hours after dosing, as observed in our second analysis (7 comparisons) with similar effects in ketamine-treated and control animals. Chronic ketamine administration (9 comparisons) caused profound relief of allodynia when tested during ketamine exposure (effect size 5.1, 3.7-6.5). The final analysis (6 comparisons) showed that chronic administration caused a slow loss of relief of allodynia with 70% loss of effect 24 days after end of treatment. No subgroups analyses were possible in the last 3 meta-analyses due to small group sizes. These results indicate long-term ketamine anti-allodynic effects after chronic exposure (>3 days) but not after a single administration. Given several limitations, extrapolation of the animal data to the human condition is tenuous.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association for the Study of Pain.

Figures

Figure 1.
Figure 1.
Flowchart of study search and selection process.
Figure 2.
Figure 2.
(A) Main characteristics of studies selected in the meta-analysis. Pain models: SCI, spinal cord injury; SNL, spinal nerve ligation; SNI, spared nerve injury; CCI, chronic nerve constriction injury; and “other” pain models were constriction of infraorbital nerve (n = 1), brachial plexus ablation (n = 1), postherpetic neuralgia (n = 1), and streptozotocin-induced neuropathy (n = 1). Administration route: i.t., intrathecal; i.p., intraperitoneal; and “other” routes were subcutaneous (n = 2), intranasal (n = 1), and intravenous (n = 2). Measurement techniques: “other” includes measuring withdrawal latency to cold and heat stimuli. (B) Summary of the 4 meta-analyses. No delay indicates that the measurement of neuropathic pain was performed during the period of ketamine administration. The data point of the single administration 24-72 h is without Fang et al. (Ref. 11).
Figure 3.
Figure 3.
(A) Risk of bias assessment of the included studies. (B) Reporting questions on randomization, blinding, and power calculation.
Figure 4.
Figure 4.
(A) Forest plot of the effect of a single ketamine injection on neuropathic pain measured within 3 hours of injection. (B) Forest plot of the effect of a single ketamine injection on neuropathic pain measured at 24 or 72 hours after injection. (C) Forest plot of the effect of repetitive ketamine injections or a continuous infusion on neuropathic pain, measured during ketamine administration. (D) Forest plot of the effect of repetitive ketamine injections or a continuous infusion on neuropathic pain, measured in the days after ketamine administration. The green diamonds are the group effect sizes ± 95% confidence intervals.
Figure 5.
Figure 5.
Subgroups of comparisons on the effect of a single administration of ketamine on relief of allodynia measured within 3 hours of administration. The data are pooled effect size (Hedges g) ± 95% confidence interval. The dotted line and gray area are the effect size of all the complete data set ± 95% confidence interval. CCI, chronic nerve constriction injury; i.t., intrathecal; SNL spinal nerve ligation injury.
Figure 6.
Figure 6.
Funnel plot of meta-analysis 1 examining the ketamine effect within 3 hours of a single administration. Each symbol represents an independent comparison.

References

    1. Bell RF, Kalso EA. Ketamine for pain management. Pain Rep 2018;3:e674.
    1. Chaplan SR, Malmberg AB, Yaksh TL. Effect of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. J Pharmacol Exp Ther 1997;280:829–38.
    1. Christoph T, Schiene K, Engelberger W, Parsons CG, Chizh BA. The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism. Neuropharmacol 2006;51:12–7.
    1. Claudino R, Nones C, Araya E, Chicorro J. Analgesic effects of intranasal ketamine in rat models of facial pain. J Oral Facial Pain Headache 2018;32:238–46.
    1. Dahan A, Olofsen E, Sigtermans M, Noppers I, Niesters M, Aarts L, Bauer M, Sarton E. Population pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief of chronic pain. Eur J Pain 2011;15:258–67.
    1. Dahan A, van Velzen M, Niesters M. Ketamine for neuropathic pain: a tiger that won't bite? Br J Anaesth 2020;125:e275–6.
    1. de Vries RBM, Hooijmans CR, Langendam MW, van Luijk J, Leenaars M, Ritskes-Hitinga M, Wever KE. A protocol format for the preparation, registration and publication of systematic reviews of animal intervention studies. Evidence Based Preclin Med 2015;1:1–9(e00007).
    1. De Vry J, Kuhl E, Franken-Kunkel P, Eckel G. Pharmacological characterization of the chronic constriction injury model of neuropathic pain. Eur J Pharmacol 2004;491:137–48.
    1. Dickenson AH. A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol Sci 1990;11:307–9.
    1. Doncheva ND, Vasileva L, Saracheva K, Dimitrova D, Getova D. Study of antinociceptive effect of ketamine in acute and neuropathic pain models in rats. Adv Clin Exp Med 2019;28:573–9.
    1. Fang X, Zhan G, Zhang J, Xu H, Zhu B, Hu Y, Yang C, Luo A. Chronic neuropathic pain-related anhedonia in a rat model of spared nerve injury. Clin Psychopharmacol Neurosci 2019;17:189–99.
    1. Hama A, Sagen J. Combinations of intrathecal gamma-amino-butyrate receptor agonists and N-methyl-d-aspartate receptor antagonists in rats with neuropathic spinal cord injury pain. Eur J Pharmacol 2012;683:101–8.
    1. Hooijmans CR, de Vries RBM, Ritskes-Hoitinga M, Rovers MM, Leeflang MM, IntHout J, Wever KE, Hooft L, de Beer H, Kuijpers T, Macleod MR, Sena ES, ter Riet G, Morgan RL, Thayer KA, Rooney AA, Guyatt GH, Schünemann HJ, Langendam MW. GRADE working group. Facilitating healthcare decisions by assessing the certainty in the evidence from preclinical animal studies. PLoS ONE 2018;13:e0187271.
    1. Hooijmans CR, IntHout J, Ritskes-Hoitinga M, Rovers MM. Meta-analyses of animal studies: an introduction of a valuable instrument to further improve healthcare. ILAR J 2014;55:418–26.
    1. Hooijmans CR, Rovers MM, de Vries RBM, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE's risk of bias tool for animal studies. Med Res Method 2014;14:43.
    1. Hooijmans CR, Tillema A, Leenaars M, Ritskes-Hoitinga M. Enhancing search efficacy by means of a search filter for finding all studies on animal experimentation in PubMed. Lab Anim 2010;44:170–5.
    1. Hota D, Bansal V, Pattanaik S. Evaluation of ketamine, nimodipine, gabapentin and imipramine in partial sciatic nerve transection model of neuropathic pain in rat: an experimental study. Meth Find Exp Clin Pharmacol 2007;29:443–6.
    1. Huang C, Li HT, Shi YS, Han JS, Wan Y. Ketamine potentiates the effect of electroacupuncture on mechanical allodynia in a rat model of neuropathic pain. Neurosci Let 2004;368:327–31.
    1. Humo M, Ayazgök B, Becker LJ, Waltisperger E, Rantamäki T, Yalcin I. Ketamine induces rapid and sustained antidepressant-like effects in chronic pain induced depression: role of MAPK signaling pathways. Progr Neuropsychopharmacol Biol Psychiat 2020;100:109898.
    1. Jonkman K, Dahan A, van de Donk T, Aarts L, Niesters M, van Velzen M. Ketamine for pain. F1000Res 2017;6:1711.
    1. Kamp J, van Velzen M, Olofsen E, Boon M, Dahan A, Niesters M. Pharmacokinetic and pharmacodynamic considerations for NMDA-receptor antagonist ketamine in the treatment of chronic neuropathic pain: an update of the most recent literature. Exp Opin Drug Metab Toxicol 2019;15:1033–41.
    1. Kroin JS, Das V, Moric M, Buvanendran A. Efficacy of the ketamine metabolite (2R,6R)-hydroxynorketamine in mice models of pain. Reg Anesth Pain Med 2019;44:111–7.
    1. Kwon SY, Yeom JH, Joo JD. Ketamine reduces the induced spinal p38 MAPK and proinflammatory cytokines in a neuropathic rats. Kor J Anesthesiol 2014;66:52–8.
    1. Li Y, Shen R, Wen G, Ding R, Du A, Zhou J, Dong Z, Ren X, Yao H, Zhao R, Zhang G, Lu Y, Wu X. Effects of ketamine on levels of inflammatory cytokines IK-6, Il-1β, and TNF-α in the hippocampus of mice following acute or chronic administration. Front Pharmacol 2017;8:139.
    1. Lim HS, Kim JM, Choi JG, Ko YK, Shin YS, Jeon BH, Park JB, Lee JH, Kim HW. Intrathecal ketamine and pregabalin at sub-effective doses synergistically reduces neuropathic pain without motor dysfunction in mice. Biol Pharm Bull 2013;36:125–30.
    1. Mak P, Broadbear JH, Kolosov A, Goodchild CS. Long-term antihyperalgesic and opioid-sparing effects of 5-day ketamine and morphine infusion (“burst ketamine”) in diabetic neuropathic rats. Pain Med 2015;16:1781–93.
    1. Mao J, Price DD, Hayes RL, Lu J, Mayer DJ, Frenk H. Intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviors in a rat model of peripheral mononeuropathy. Brain Res 1993;605:164–8.
    1. M'Dahoma S, Bourgoin S, Kayser V, Bartélémy S, Chevarin C, Chali F, Orsal D, Hamon M. Spinal cord transection-induced allodynia in rats—behavioral, physiopathological and pharmacological characterization. PLoS One 2014;9:e102027.
    1. M'Dahoma S, Barthélemy S, Tromilin C, Jeanson T, Viguier F, Michot B, Pezet S, Hamon M, Bourgoin S. Respective pharmacological features of neuropathic-like pain evoked by intrathecal BDNF versus sciatic nerve ligation in rats. Eur Neuropsychopharmacol 2015;25:2118–30.
    1. Mehta AK, Halder S, Khanna N, Tandom OP, Singh UR, Sharma KK. Role of NMDA and opioid receptors in neuropathic pain induced by chronic constriction injury of sciatic nerve in rats. J Basic Clin Physiol Pharmacol 2012;23:49–55.
    1. Mei X, Wang W, Wang W, Li Y, Zhang H, Wu S, Li Y, Xu L. Inhibiting astrocyte activation: a novel analgesic mechanism of ketamine at the spinal level? J Neurochem 2009;109:1691–700.
    1. Mei XP, Wang W, Wang W, Li Y, Zhang H, Wu S, Li Y, Xu L. Combining ketamine with astrocytic inhibitor as a potential analgesic strategy for neuropathic pain—ketamine, astrocytic inhibitor and pain. Mol Pain 2010;6:50.
    1. Mei XP, Zhang H, Wang W, Wei YY, Zhai MZ, Wang W, Xu LX, Li YQ. Inhibition of spinal astrocytic c-Jun N-terminal kinase (JNK) activation correlates with the analgesic effects of ketamine in neuropathic pain. J Neuroinflamm 2011;8:6.
    1. Mei XP, Zhou Y, Wang W, Tang J, Wang W, Zhang H, Xu LX, Li YQ. Ketamine depresses Toll-like receptor 3 signaling in spinal microglia in a rat model of neuropathic pain. Neurosignals 2011;19:44–53.
    1. Michelet D, Brasher C, Horlin AL, Bellon M, Julien-Marsollier F, Vacher T, Pontone S, Dahmani S. Ketamine chronic non-cancer pain: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur J Pain 2018;22:632–46.
    1. Mogil JS. Qualitative sex differences in pain processing: emerging evidence of a biased literature. Nat Rev Neurosci 2020;21:353–65.
    1. Niesters M, Khalili-Mahani N, Martini C, Aarts L, van Gerven J, van Buchem MA, Dahan A, Rombouts S. Effect of sub-anesthetic ketamine on intrinsic functional brain connectivity: a placebo-controlled functional magnetic resonance imaging study in healthy volunteers. Anesthesiology 2012;117:868–77.
    1. Noppers I, Niesters M, Aarts L, Smith T, Sarton E, Dahan A. Ketamine for treatment of chronic non-cancer pain (Review). Expert Opin Pharmacother 2010;11:2417–29.
    1. Orser B, Pennefather PS, MacDonald JF. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology 1997;86:903–17.
    1. Pan W, Zhang GF, Li HH, Li MH, Zhou ZQ, Li KY, Yang JJ. Ketamine differentially restores diverse alterations of neuroligins in brain regions in a rat model of neuropathic pain-induced depression. NeuroRep 2018;29:863–9.
    1. Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-d-aspartate (NMDA) receptors in pain: a review. Anesth Analg 2003;97:1108–16.
    1. Pickering G, Pereira B, Morel VC, Corriger A, Giron F, Mercaillou F, Bidar-Beauvallot A, Chandeze E, Lambert C, Bernard L, Delage N. Ketamine and magnesium for refractory neuropathic pain: a randomized, double-blind, crossover trial. Anesthesiology 2020;133:154–64.
    1. Qian J, Brown SD, Carlton SM. Systemic ketamine attenuates nociceptive behaviors in a rat model of peripheral neuropathy. Brain Res 1996;715:51–62.
    1. Rice ASC, Cimino-Brown D, Eisenach JC, Kontinen VK, Lacroix-Fralish ML, Machin I; Preclinical Pain Consortium, Mogil JS, Stöhr T. Animal models and the prediction of efficacy in clinical trials of analgesic drugs; a critical appraisal and call for uniform reporting standards. PAIN 2009;139:243–7.
    1. Rodrigues-Filho R, Campos MM, Ferreira J, Santos ARS, Bertelli JA, Calixto JB. Pharmacological characterization of the rat brachial plexus avulsion model of neuropathic pain. Brain Res 2004;1018:159–70.
    1. Salvat E, Yalcin I, Muller A, Barrot M. A comparison of early and late treatments on allodynia and its chronification in experimental neuropathic pain. Mol Pain 2018;14:1–10.
    1. Sasaki A, Serizawa K, Andoh T, Shiraki K, Takahata H, Kuraishi Y. Pharmacological differences between static and dynamic allodynia in mice with herpetic or postherpetic pain. J Pharmacol Sci 2008;108:266–73.
    1. Sigtermans M, Noppers I, Sarton E, Bauer M, Mooren R, Olofsen E, Dahan A. An observational study on the effect of S(+)-ketamine on chronic pain versus experimental acute pain in Complex Regional Pain Syndrome type 1 patients. Eur J Pain 2010;14:302–7.
    1. Sleigh J, Harvey M, Voss L, Denny B. Ketamine—more mechanisms than just NMDA blockade. Trends Anaesth Crit Care 2014;4:76–81.
    1. Swartjes M, Morariu A, Niesters M, Aarts L, Dahan A. Non-selective and NR2B-selective NMDA receptor antagonists produce antinociception and long-term relief of allodynia in acute and neuropathic pain. Anesthesiology 2011;115:165–74.
    1. Swartjes M, Niesters M, Heij L, Dunne A, Aarts L, Cerami Hand C, Kim HS, Brines M, Cerami A, Dahan A. Ketamine does not produce relief of neuropathic pain in mice lacking the β-common receptor (CD131). PLoS One 2013;8:e71326.
    1. Truin M, Janssen SPM, van Kleef M, Joosten EAJ. Successful pain relief in non-responders to spinal cord stimulation: the combined use of ketamine and spinal cord stimulation. Eur J Pain 2011;15:1049.e1–9.
    1. Wang J, Goffer Y, Xu D, Tukey DS, Shamir DB, Eberle SE, Zou AH, Blanck TJJ, Ziff EB. A single subanesthetic dose of ketamine relieves depression-like behaviors induced by neuropathic pain in rats. Anesthesiology 2011;115:812–21.
    1. Zwetsloot PP, van der Naald M, Sena ES, Howells DW, IntHout J, de Groot JAH, Chamuleau SAJ, MacLeod MR, Wever KE. Standardized mean differences cause funnel plot distortion in publication bias assessments. eLife 2017;6:24260.

Source: PubMed

3
Sottoscrivi